Earn Your Leisure

In this Market Mondays clip, Rashad Bilal, Troy Millings, and Ian Dunlap dive deep into the multi-billion dollar lawsuits facing pharmaceutical giants Novo Nordisk and Eli Lilly over their blockbuster drug Ozempic and similar weight loss treatments. With over 2,000 federal lawsuits piling up—worth more than $2 billion—the team explores the risks and side effects, including rare vision problems, stomach paralysis, and severe kidney damage, now at the center of these legal battles.Rashad shares his early warnings about the rapid rise of Ozempic and reflects on the cyclical history of “miracle” weight loss drugs that ultimately face safety concerns and legal troubles. Drawing a parallel from global affairs and the importance of studying history—whether in geopolitics or investing—the hosts break down why this pattern was predictable and how investors can learn from it.Troy and Ian highlight the importance of understanding a company’s product portfolio, leadership, and resilience in the face of crisis, comparing